Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden:

Tomas Bro,Staffan Hägg

Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden:

2019

Tomas Bro
Staffan Hägg

Purpose:To examine the clinical effects of switching intravitreal drug treatment from the approved vascular endothelial growth factor inhibitors, ranibizumab and aflibercept, to off label use of be...

Keywords:

Off-label use
Aflibercept
Ranibizumab
Diabetes mellitus
Macular degeneration
Ophthalmology
Surgery
Medicine
Bevacizumab
Vascular endothelial growth factor
age related
intravitreal ranibizumab
drug treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations